International Conference on Dupuytren Disease and Related Disorders
Groningen, The Netherlands
Day 1 Friday, 22 May 15
08:00
08:30
08:35
08:40
08:45
09:05
Registration
Welcome
Paul Werker
Jos Aartsen CEO UMCG
Wolfgang Wach & Charles Eaton
Lecture : Treatment of Dupuytren in Zolt Szabo
Chair : Paul different countries and the role of FESSH Werker
and IFSSH in promoting knowledge for hand surgeons
Session 1: Epidemiology & Patients Views Chair : Bert Reichert & Zsolt Szabo
09:05
The epidemiology of surgical intervention Joe Dias
for Dupuytren's Contracture in England
09:11
Favorite Options of German Hand Surgeons Bert Reichert
in the Treatment of Dupuytren Disease
09:17
Trends in Dupuytren’s Treatment in the United States
Discussion
The Patient’s View and Needs – An International Survey: Dupuytren Disease
Patients’ preferences for treatment for Dupuytren’s disease: a Discrete Choice Experiment
Discussion
Coffee Break
Lecture : The extra-‐cellular matrix in Dupuytren's disease
09:23
09:38
09:44
09:50
10:00
10:30
10:50
10:50
10:56
11:02
11:08
Session 2: Cellular and extracellular events
PDGFR-‐β targeted modified interferon gamma in Dupuytren’s disease
Wnt pathway in Dupuytren disease, connecting pro-‐fibrotic signals
Biomarkers of post-‐surgical outcome in Dupuytren’s disease
Tumour necrosis factor (TNF) as a therapeutic target in Dupuytren’s disease
Philip Blazar
Wolfgang Wach
Hester Kan
David O'Gorman
Chair : Boris Hinz & Ruud Bank
Chair : Boris Hinz & Ruud Bank
Marianna Kruithof-‐de Julio
Marike van Beuge
Ian Clark
Jagdeep Nanchahal
11:14
11:30
11:32
11:37
11:42
12:00
13:00
13:20
13:20
13:26
13:32
13:38
13:53
13:59
14:05
14:15
14:17
14:22
14:27
14:45
15:15
15:35
15:35
Discussion
Controversies 1: Pathogenesis of Dupuytren Disease; active or passive contracture?
Active Contracture
Passive Contracture
Audience response
Lunch
Lecture : Genetics in Dupuytren Disease
Chair : David O'Gorman
Jagdeep Nanchahal
Charles Eaton
Roel Ophoff
Chair : Hans Hennies
Chair : Roel Ophoff & Hans Hennies
Michael Ng
Session 3: Genetics & Associations
A Large European Genome-‐wide Association Study Reveals Multiple New Genetic Susceptibility Variants for Dupuytren's Disease
Meta-‐analysis of genome-‐wide imputed Kerstin Becker
GWAS identifies new significant loci in patients with Dupuytren´s disease
Identification and characterization of Juanjiangmeng Du
functional genetic variants in Dupuytren’s Disease
Discussion
A systematic review and meta-‐analysis on Dieuwke Broekstra
the association between Dupuytren disease and diabetes
The association between vibration and Dieuwke Broekstra
Dupuytren disease: a comparison between elderly field hockey players and controls
Discussion
Controversies 2: The benefit of splinting for Chair : Ilse Degreef
Dupuytren Contracture
Splinting confers no benefit
Adrian Chojnowski
Splinting is beneficial
Wolfgang Wach
Audience response
Coffee Break
Lecture : Collagenase Treatment - Larry Hurst
Journey from Bench to Current
Advanced Clinical Use
Chair : Steve Coleman & Stephan Wilbrand
Session 4: Collagenase Injection
Chair : Steve Coleman & Stephan Wilbrand
Dupuytren's Disease in the thumb and first Paul Werker
webspace and collagenase treatment
15:41
15:47
15:53
15:59
16:19
16:24
16:30
16:36
16:42
16:48
Efficacy of using local anesthesia before Jesper Nordenskjöld
collagenase injection in reducing overall pain experience in patients treated for Dupuytren’s contracture: A quasi-‐
randomized study
Effect of Delayed Finger Extension on the Gary M. Pess
Efficacy and Safety of Collagenase Clostridium Histolyticum Treatment for Dupuytren’s Contracture
The use of a dynamic dorsal splint for Massimo Corain
Dupuytren Rehabilitation after collagenase
Discussion
Dupuytren Award 2014
Wolfgang Wach & Paul Werker
Treatment with Collagenase Clostridium Clayton A. Peimer
Histolyticum: Five-‐Year CORDLESS Data
Prospective Multicenter, Multinational Marie Badalamente
Study to Evaluate the Safety and Efficacy of Concurrent Collagenase Clostridium Histolyticum Injections to Treat Two Dupuytren’s Contractures in the Same Hand
An Open-‐label, Controlled Phase 2a Study Marie Badalamente
of the Safety and Efficacy of Injectable Collagenase Clostridium Histolyticum (CCH) in Patients with Adhesive Capsulitis (Frozen Shoulder)
Collagenase-‐ what we may never know-‐ a David Warwick
discussion paper
Discussion
17:04
17:06
17:11
17:16
17:34
Controversies 3: The best minimally Chair : Charles Eaton
invasive treatment for Dupuytren Disease: PNF or Collagenase?
Percutaneous Needle Fasciotomy
Paul Werker
Collagenase
David Warwick
Audience Response
Day 2 Saturday, 23 May 15
08:00
08:30
08:30
08:36
08:42
08:48
09:03
09:09
09:15
09:21
09:37
09:41
09:46
09:51
10:15
Registration
Session 5: Assessment/ Percutaneous Needle Fasciotomy
MCID for the Patient Evaluation Measure as a Patient Rated Outcome Measure for Dupuytren Contracture
Predictors of Satisfaction with Hand Function in Patients with Dupuytren’s Disease
URAMS as a PROM for Dupuytren Contracture Patients
Discussion
Tips and Pearls for Percutaneous Needle Fasciotomy and Collagenase -‐ A Ten Year Personal Experience
Percutaneous Needle Fasciotomy for secondary or higher recurrence in Dupuytren’s disease
Extensive Percutaneous Aponeurotomy and Lipofilling versus Limited Fasciectomy in Patients with Primary Dupuytren’s Contracture; a Randomized Controlled Trial
Discussion
Controversies 4: How to treat severe PIP contractures: minimally invasive of surgically?
Minimally invasive methods
Surgical correction
Audience response
Coffee Break
Chair : Gary Pess & Ulrich Lanz
Joe Dias
Chao Zhou
Joe Dias
Gary Pess
Margot Vlot
Steven Hovius
Chair : Joe Dias
Clayton Peimer
Caroline Leclercq
10:45
Lecture : Treatment of Dupuytren Disease: Where are we now
11:05
Session 6: Comparative Studies/ Chair : Caroline Leclercq & David Elliot
Recurrence
Steroid injection and needle Paul Binhammer
aponeurotomy for Dupuytren disease: long-‐
term follow-‐up of a randomized controlled trial
Minimal invasive treatment of Duputren: Eva-‐Maria Baur
Collagenase vs. PNF
Collagenase Clostridium Histolyticum Chao Zhou
versus Partial Fasciectomy for Dupuytren's contracture: Early Outcomes From A Multicenter Propensity-‐Score Matched Study
Discussion
Actual Indications of Continuous Extension Jane C Messina
Technique (TEC) For Severe Dupuytren Disease
Preliminary soft-‐tissue distraction versus Atanu Biswas
checkrein ligament release after fasciectomy in the treatment of Dupuytren proximal interphalangeal joint contractures
11:05
11:11
11:17
11:23
11:35
11:41
11:47
11:55
12:01
12:07
12:15
12:21
12:27
12:33
12:45
13:45
13:50
Discussion
The Palmodigital Spiralling Sheath
Clusters in short term disease course in participants with primary Dupuytren Disease
Discussion
Recurrence after Treatment for Dupuytren’s Disease; A consensus-‐based definition
Recurrence after Dupuytren’s disease: the time factor
Is Recurrence of Dupuytren Disease Prevented by Full-‐Thickness Grafting Surgery?
Discussion
Lunch
Housekeeping
Lecture : Radiotherapy for Early Stage Dupuytren and Ledderhose Disease
David Elliot
Chair : Caroline Leclercq
Rinze Lykele Zwanenburg
Rosanne Lanting
Ruud Selles
Caroline Leclercq
Ilse Degreef
Heinrich Seegenschmiedt
Chair : Richard Shaffer & Ruud Selles
14:10
14:10
14:16
14:22
14:32
14:38
14:44
14:54
15:05
15:35
15:40
16:30
17:20
Session 7: Related disease & Other Treatments
A Systematic Review Of Non-‐Surgical Treatments For Early Dupuytren’s Disease
The Patient’s View and Needs – An International Survey: Ledderhose Disease
Discussion
Use of Acellular Dermal Matrix in Dupuytren Disease
Tension versus compression on Dupuytren
Discussion
Lecture : Peyronie's Disease Treatment: The State of the Art
Coffee Break
Focus on Research: Introduction to the symposia
Basic Research: important prerequisites for future studies
Clinical Research: international collaboration to execute high powered clinical trials
Close
Chair : Richard Shaffer & Ruud Selles
Catherine Ball
Gary Manley
Gloria Sue
Ilse Degreef
Mels van Driel
Joe Dias
Chair : David O'Gorman
Chair : Marie Badalamente
Wolfgang Wach, Charles Eaton & Paul Werker
1
2
3
4
5
6
7
8
9
10
11
Posters
Elevated cAMP Inhibits both Basal-‐ and Latha Satish
PDGF-‐Induced Cell Migration and Contraction in Dupuytren’s Contracture-‐
Derived Fibroblasts
Correlation of function with deformity in David Warwick
Dupuytren’s Disease-‐ the condition specific Southampton Scoring Scheme outperforms the generic QuickDASH
Tonometry as an outcome measure for the Catherine Ball
treatment of Dupuytren’s disease
Intra-‐ and inter-‐observer agreement on Dieuwke Broekstra
diagnosis and measurements of Dupuytren disease severity
Variation in range of movement reporting Anna Pratt
in Dupuytren’s disease
Experience of Treating Patients with Stage Andrey Zhigalo
IV Dupuytren Contracture
Six Years Experience of Using Needle Andrey Zhigalo
Aponeurotomy when Treating Patients with Dupuytren's Disease
YAP1 is a driver of myofibroblast Bram Piersma
differentiation in normal and Dupuytren’s fibroblasts
Clinical Validation of Pharmacoeconomic Rafael Sanjuan
Model in Dupuytren Contracture
Collagenase versus Fasciectomy in Rafael Sanjuan
Dupuytren Dissease: Cost-‐Utility Analysis
Origin of Dupuytren’s myofibroblasts in an Sofia Karkampouna
ex vivo tissue culture system